(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Ghiath M. Sukhtian, 10% Owner, Director, on November 29, 2021, executed a purchase for 16,000,000 shares in Outlook Therapeutics (OTLK) for $20,000,000....
Outlook Therapeutics (OTLK) on Tuesday increased its previously announced bought-deal offering of common shares to $50 million in gross proceeds from the...
Outlook Therapeutics (OTLK) said late Tuesday it agreed to a bought-deal offering of common stock allowing underwriter HC Wainwright to buy 8 million...
| Address | 485 Route 1 South Iselin, New Jersey 08830 |
| Phone | +1.609.619.3990 |
| Number of Employees | 56 |
| Recent SEC Filing | 12/23/2021 10-K |
| President, Chief Executive Officer & Director | C. Russell Trenary |
| Chief Operating Officer | Terry Dagnon |
| CFO, Secretary, Treasurer & Director | Lawrence A. Kenyon |
| Senior Vice President-Clinical Development | Jennifer M. Kissner |
| Price Open | $1.30 |
| Previous Close | $1.30 |
| 52 Week Range | $0.93 - 4.26 |
| Market Capitalization | $298.3 M |
| Shares Outstanding | 224.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/15/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.36 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.1 M |
| Net Profit Margin | N/A |
| Return on Equity | -772.36% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
